论文部分内容阅读
目的:观察参麦注射液辅助机械通气治疗慢性阻塞性肺疾病急性加重期(AECOPD)并Ⅱ型呼吸衰竭的临床疗效。方法:选择56例机械通气治疗的AECOPD并Ⅱ型呼吸衰竭患者,随机分为2组,对照组予抗感染、机械通气等常规治疗,观察组在此基础上联合应用参麦注射液,比较2组的临床疗效、机械通气时间、治疗2周后的急性生理学与慢性健康状况Ⅱ(APACHEⅡ)评分、ICU住院时间及呼吸机相关性肺炎(VAP)的发生率。结果:观察组总有效率为92.86%,高于对照组的71.43%(P<0.05)。观察组机械通气时间、APACHEⅡ评分、ICU住院时间及VAP发生率均低于对照组,差异均有统计学意义(P<0.05)。结论:参麦注射液辅助机械通气治疗AECOPD并Ⅱ型呼吸衰竭患者,可有效改善临床症状体征,有利于感染的控制及肺功能的恢复。
Objective: To observe the clinical efficacy of Shenmai injection-assisted mechanical ventilation in the treatment of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and type Ⅱ respiratory failure. Methods: Fifty-six patients with AECOPD and type Ⅱ respiratory failure who were treated with mechanical ventilation were randomly divided into two groups. The control group was treated with anti-infection and mechanical ventilation. The observation group was treated with Shenmai injection, The clinical efficacy, duration of mechanical ventilation, acute physiology and chronic health status II (APACHE II) scores after 2 weeks of treatment, ICU length of hospital stay and the incidence of ventilator-associated pneumonia (VAP) were evaluated. Results: The total effective rate in the observation group was 92.86%, which was higher than 71.43% in the control group (P <0.05). The duration of mechanical ventilation, the APACHEⅡscore, the length of hospital stay and the incidence of VAP in the observation group were all lower than those in the control group, with significant differences (P <0.05). Conclusion: Shenmai injection assisted mechanical ventilation in patients with AECOPD and type Ⅱ respiratory failure can effectively improve clinical symptoms and signs, which is good for infection control and lung function recovery.